Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
jing, xu
NCT05417841: Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM	Not yet recruiting	N/A	224	RoW	Insulin Degludec and Insulin Aspart Injection, Ryzodeg®, Insulin Aspart Injection, NovoRapid®	Beijing Hospital	Type 2 Diabetes Mellitus	12/23	07/24